The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Living Donor Liver Transplantation for Early Hepatocellular Carcinoma: A Life–Expectancy and Cost–Effectiveness Perspective
Open accessAbstract
Cadaveric liver transplantation (CLT) is an excellent treatment for early hepatocellular carcinoma (HCC). Its use, however, is limited by the shortage of grafts, with up to 30% of patients developing contraindications to the procedure while waiting for a donor. Living donor liver transplantation (LDLT) has emerged as an alternative to overcome this limitation. We compared the consequences of LDLT versus CLT using a Markov model balancing the gains and losses in life expectancy among donors and recipients. For a 60–year–old recipient with a 70% 5–year survival after transplantation, a 4% monthly drop–out rate, and a donor with 1% mortality, LDLT became more effective than CLT after 3.5 months on the waiting list. These results varied with the probability of developing contraindications to transplantation, the survival after transplantation, and the donor's mortality. For a 12–month delay saved on the waiting list, the gain in survival provided by LDLT compared with CLT ranged between 0 and 2.8 life years depending on survival after transplantation, time spent on the waiting list, and drop–out rate. LDLT was cost–effective (less than $50,000 per quality–adjusted life year saved) in all scenarios of waiting lists exceeding 7 months, and this figure ranged from 2 to 16 months when varying the drop–out rate. LDLT for early HCC offered substantial gains in life expectancy with acceptable cost–effectiveness ratios when the waiting list exceeds 7 months. The gain in life expectancy and the cost–effectiveness of LDLT were more dependent on the drop–out rate and the outcome after transplantation than on donor's mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Measuring Health-Related Quality of Life
Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00009 · Cited by 3,958
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Self-citationLlovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Self-citationRecommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147
Compensated cirrhosis: Natural history and prognostic factors
Ginés, P., Quintero, E., Arroyo, V., Terés, J., Bruguera, M., Rimola, A., Caballería, J., Rodés, J., & Rozman, C. (1987) · Hepatology · doi:10.1002/hep.1840070124 · Cited by 1,106
Utility approach to measuring health-related quality of life
Torrance, G. W. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90019-1 · Cited by 1,072
Siegel, J. E. (1996) · JAMA · doi:10.1001/jama.276.16.1339 · Cited by 1,037
Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends
Wasley, A., & Alter, M. J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9506 · Cited by 979
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Cost–effectiveness studies suggested that LDLT can be offered to patients with HCC if the waiting list exceeds 7 months [248], a policy adopted by the panel.”
BackgroundLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationPrognostic prediction and treatment strategy in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2002) · Hepatology · doi:10.1053/jhep.2002.32089 · Cited by 1,099
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Self-citationde Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Self-citationHepatocellular carcinoma: Diagnosis and treatment
Befeler, A. S., & di Bisceglie, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33411 · Cited by 602
Hepatocellular carcinoma: From diagnosis to treatment
Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A., & Pawlik, T. M. (2016) · Surgical Oncology · doi:10.1016/j.suronc.2016.03.002 · Cited by 456
Yao, F. Y., Ferrell, L., Bass, N. M., Bacchetti, P., Ascher, N. L., & Roberts, J. P. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.34892 · Cited by 408
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Yao, F. Y., Bass, N. M., Nikolai, B., Davern, T. J., Kerlan, R., Wu, V., Ascher, N. L., & Roberts, J. P. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.34923 · Cited by 389
Adam, R., Azoulay, D., Castaing, D., Eshkenazy, R., Pascal, G., Hashizume, K., Samuel, D., & Bismuth, H. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000090449.87109.44 · Cited by 377
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Treatment of Hepatocellular Carcinoma: A Systematic Review
Lin, S., Hoffmann, K., & Schemmer, P. (2012) · Liver Cancer · doi:10.1159/000343828 · Cited by 334
Llovet, J. M. (2002) · Gut · doi:10.1136/gut.50.1.123 · Cited by 287
Self-citationOperative morbidity of living liver donors in Japan
Umeshita, K., Fujiwara, K., Kiyosawa, K., Makuuchi, M., Satomi, S., Sugimachi, K., Tanaka, K., & Monden, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14230-4 · Cited by 285
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner, R. H., Freeman, R. B., & Mulligan, D. C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.040 · Cited by 273
Fisher, R. A., Kulik, L. M., Freise, C. E., Lok, A. S. F., Shearon, T. H., Brown, R. S., Ghobrial, R. M., Fair, J. H., Olthoff, K. M., Kam, I., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01802.x · Cited by 272
Strategies for the management of hepatocellular carcinoma
Schwartz, M., Roayaie, S., & Konstadoulakis, M. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0844 · Cited by 261
Practice guidelines for management of hepatocellular carcinoma 2009
Korean Liver Cancer Study Group and National Cancer Center, K. (2009) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2009.15.3.391 · Cited by 257
Metadata
- Authors
- Sarasin, F. P., Majno, P. E., Llovet, J. M., Bruix, J., Mentha, G., & Hadengue, A.
- Venue
- Hepatology
- Published
- 2001-05
- Volume
- 33
- Issue
- 5
- Pages
- 1073-1079
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2025487438
- Cited by
- 263
- References
- 31
- FWCI
- 20.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.